19 Leukemia Clinical Trials in Minneapolis, MN (2026)

Q: How do I join a clinical trial in Minneapolis?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Minneapolis research site will contact you.

Recruiting Leukemia Studies in Minneapolis

NCT05885698Recruiting

MYLUNG Consortium Part 3: Observational Study

This longitudinal study looks to quantify the testing timeline, operational barriers, and outcomes of biomarker-guided therapy in a large, community-based, and largely unselected patient population wi...

Minneapolis, MN7,500 participantsUS Oncology Research

View Study Details

NCT05005403Recruiting

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues...

Minneapolis, MNPHASE1694 participantsAbbVie

View Study Details

NCT05744973Recruiting

Multi-level Predictors of Structural Racism and Discrimination and Associations With Health and Well-being Across the Life Course in Diverse Families

Minoritized populations face mutually reinforcing levels of structural disadvantage that contribute to poor health. Despite recognition that social and economic stratification, environmental condition...

Minneapolis, MN631 participantsUniversity of Colorado, Denver

View Study Details

NCT05786924Recruiting

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combin...

Minneapolis, MNPHASE1554 participantsInstitut de Recherches Internationales Servier

View Study Details

NCT06646276Recruiting

A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

The Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab...

Minneapolis, MNPHASE3530 participantsBristol-Myers Squibb

View Study Details

NCT03314974Recruiting

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine/busulfan for patients...

Minneapolis, MNPHASE2300 participantsMasonic Cancer Center, University of Minnesota

View Study Details

NCT05014165Recruiting

Backtracking Leukemia-Typical Somatic Mutations in Cord Blood

A comprehensive mechanistic and epidemiological study to obtain banked cord blood samples from consecutive childhood leukemia patients enrolled in the COG Project:EveryChild (APEC14B1) study. Will att...

Minneapolis, MN300 participantsChildren's Oncology Group

View Study Details

NCT04317534Recruiting

Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

A randomized trial of adjuvant Pembrolizumab following surgical resection versus observation following surgical resection in patients with stage I non-small cell lung cancer (NSCLC) with primary tumor...

Minneapolis, MNPHASE2244 participantsGreg Durm, MD

View Study Details

NCT05082519Recruiting

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to chemotherapy in patients w...

Minneapolis, MNPHASE2240 participantsEtan Orgel

View Study Details

NCT06681220Recruiting

Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC

Randomized phase 2, multicenter, biomarker directed clinical trial with a safety lead-in to assess the efficacy of Stenoparib plus Temozolomide (TMZ) in relapsed Small Cell Lung Cancer patients. Parti...

Minneapolis, MNPHASE1166 participantsVA Office of Research and Development

View Study Details

NCT07493538Recruiting

MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases

This is a Phase II study following subjects proceeding with Treosulfan (36g/m2) preparative regimen followed by a related, unrelated, or partially matched family donor stem cell infusion, with post-tr...

Minneapolis, MNPHASE2132 participantsMasonic Cancer Center, University of Minnesota

View Study Details

NCT06119685Recruiting

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), a...

Minneapolis, MNPHASE1128 participantsIndapta Therapeutics, INC.

View Study Details

NCT06362252Recruiting

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

This study is designed to evaluate the safety and efficacy of ifinatamab deruxtecan (I-DXd) in combination with immune checkpoint inhibitor (ICI) atezolizumab with or without carboplatin in participan...

Minneapolis, MNPHASE1123 participantsDaiichi Sankyo

View Study Details

NCT07216105Recruiting

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

This is a phase 1 study of FT836 administered in participants with advanced solid tumors. The primary objectives of the study are to evaluate the safety and tolerability of FT836 with or without pacli...

Minneapolis, MNPHASE1119 participantsFate Therapeutics

View Study Details

NCT05848687Recruiting

TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

The purpose of this study is to improve upon the TINI study treatment. The study will test the ability of a type of immunotherapy called blinatumomab to clear persistent leukemia. Blinatumomab targets...

Minneapolis, MNPHASE190 participantsTanja Andrea Gruber

View Study Details

NCT05805605Recruiting

Allo HSCT Using RIC and PTCy for Hematological Diseases

This is a Phase II study following subjects proceeding with our Institutional non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen followed by a related, un...

Minneapolis, MNPHASE256 participantsMasonic Cancer Center, University of Minnesota

View Study Details

NCT07012044Recruiting

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

This phase I trial tests the safety, side effects, and best dose of ASTX727 and filgrastim for the treatment of children with high risk acute myeloid leukemia that has come back after a period of impr...

Minneapolis, MNPHASE147 participantsNational Cancer Institute (NCI)

View Study Details

NCT07008638Recruiting

Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)

This is a Phase I/II study evaluating safety and efficacy of proteasome inhibitor (bortezomib) in combination with CPX-351 (liposomal daunorubicin and cytarabine) for the treatment of newly-diagnosed ...

Minneapolis, MNPHASE132 participantsMasonic Cancer Center, University of Minnesota

View Study Details

NCT07591649Recruiting

Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT

This is a multi-institutional Phase I/II study of an allogeneic KIR-HLA mismatched NK cell infusion (AdaptNK) and a short course of subcutaneous interleukin-2 (IL-2) administered after lymphodepleting...

Minneapolis, MNPHASE118 participantsMasonic Cancer Center, University of Minnesota

View Study Details

About Leukemia Clinical Trials in Minneapolis

Leukemia is a group of blood cancers that develop in the bone marrow and result in abnormal white blood cells. Types include acute myeloid (AML), acute lymphoblastic (ALL), chronic myeloid (CML), and chronic lymphocytic (CLL). Treatment varies by type and may include chemotherapy, targeted therapy, and stem cell transplant.

There are currently 19 leukemia clinical trials recruiting participants in Minneapolis, MN. These studies are seeking a combined 11,904 participants. Research is being sponsored by US Oncology Research, AbbVie, University of Colorado, Denver and 12 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Leukemia Clinical Trials in Minneapolis — FAQ

Are there leukemia clinical trials in Minneapolis?

Yes, there are 19 leukemia clinical trials currently recruiting in Minneapolis, MN. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Minneapolis?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Minneapolis research site will contact you about next steps.

Are clinical trials in Minneapolis free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Minneapolis studies also compensate for your time and travel.

What leukemia treatments are being tested?

The 19 active trials in Minneapolis are testing new therapies including novel drugs, biologics, and treatment approaches for leukemia.

Data updated October 17, 2026 from ClinicalTrials.gov